NAFLD

Overview

Non-alcoholic fatty liver disease (NAFLD), now increasingly termed MASLD (metabolic-associated steatotic liver disease), ranges from simple steatosis to NASH (non-alcoholic steatohepatitis) and cirrhosis. Retatrutide has produced the most dramatic liver fat reduction of any peptide studied — 82.4% relative reduction in liver fat in clinical trials, making it a potential game-changer for this condition. Mitochondrial support and GH axis restoration address root metabolic drivers.

Recommended Peptides

Retatrutide – 82.4% relative reduction in liver fat demonstrated in Phase 2 trials; triple agonist mechanism reduces hepatic lipogenesis, promotes fatty acid oxidation, and reduces hepatic inflammation; the most potent anti-NAFLD peptide known
Tesamorelin – GHRH analogue with specific approval for HIV-associated lipodystrophy; reduces hepatic fat accumulation and improves liver enzyme profiles; well-studied
MOTS-C – mitochondrial peptide that reduces hepatic lipid accumulation by improving mitochondrial fatty acid oxidation in hepatocytes
SS-31 – mitochondria-targeted antioxidant; reduces hepatic oxidative stress and mitochondrial dysfunction central to NASH progression
BAM15 – mitochondrial uncoupler; reduces hepatic steatosis and inflammatory lipid species (ceramides, diacylglycerols) in preclinical models (NOT a peptide; preclinical only)

Protocols

Related Conditions

Research Summary

Tesamorelin reduces hepatic fat fraction significantly in HIV-associated NAFLD (PMID-25038357). Semaglutide shows benefits for NAFLD/MASH as demonstrated in obesity trials. Retatrutide achieved 82.4% liver fat reduction vs 0.3% placebo in Phase 2a MASLD trial (PMID-38858523). Survodutide (dual GLP-1/glucagon) showed significant MASH improvement in Phase 2 (PMID-38847460).

#condition #gastrointestinal